Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants Who Were Previously Treated for Advanced Malignancies

NCT07644039 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT07644039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07644039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants Who Were Previously Treated for Advanced Malignancies
Lead sponsor
PharmaMar
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 21, 2026
Completion date
April 2, 2029
Enrollment
119 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies